Amarin Corp Plc (AMRN)

[TalShu]

Number sleven,

I really appreciate your search for a meaningful strategy behind the Ricordati deal.
Maybe the following notes can guide us in this direction.

1. CVC CAPITAL PARTNERS Plc

CVC Capital Partners plc is a Jersey-based private equity and investment advisory firm with approximately €186 billion of assets under management and approximately €157 billion in secured commitments since inception across American, European, and Asian private equity, secondaries, credit funds and infrastructure.

Funds committed: EUR121billion

World-class platform developed over 40 years.
With over 185 investment professionals across its network of 14 offices, CVC is a world leader in European and American buyouts.
million patients a year.

2. CVC subsidiaries

2.1 In 2018 CVC Capital Partners acquired controlling stake in Ricordati
S.p.A.

https://www.cvc.com/media/news/2018/2018-06-29-cvc-fund-vii-acquires-controlling-stake-in-recordati-spa/

https://recordati.com/cvc-fund-vii-acquires-controlling-stake-in-recordati-s-p-a-2018-06-29-110100-business-financial-news/

2.2 To get a sense of what CVC Capital Partners is visit their website

https://www.cvc.com/media/bu5gdxeb/cvc-annual-report-and-accounts-2024.pdf

2.3 And in CVC’s Annual Report & Accounts 2024

check pages 237-240 “Notes to the consolidated Financial Statements” to get an idea of the companies acquired as of 30 April 2024.

3. The Ricordati Exclusive License & Supply Agreement to commercialize VAZKEPA in Europe

Odysseas Kostas, M.D., Chairman of the Amarin Board of Directors, said, “Over the last couple of years, we have done a lot to thoughtfully redesign our operations and strategy in Europe, and we are proud of the efforts and accomplishments of the team in Europe. That said, partnering with Recordati, a market leader in Europe, is now the right decision for the company, financially and for patients.”

Dr. Kostas continued, “We are pleased to place VAZKEPA, a drug with proven, meaningful cardiovascular benefit when added to statins, in the hands of a partner with the capabilities and experience in the cardiovascular space in Europe as Recordati. We believe this partnership for VAZKEPA positions both companies to benefit from future sales growth. Looking forward, Amarin will continue to pursue all options to further maximize long-term shareholder value.”

“Recordati is a highly successful, well-established partner uniquely positioned to maximize the commercial opportunity for VAZKEPA in Europe. We are confident in Recordati’s ability to lead the next phase of growth and impact patient care with VAZKEPA throughout Europe,” Mr. Berg concluded.

4. In the June 24, 2025 Investor Presentation of AMARIN’s REFINED STRATEGY:

4.1 Revised potential strategies for reimbursement in France and Germany
identified.

Part of CVC Group is French company ELSAN

Elsan is a leading private healthcare provider in France and has effectively reshaped the French private hospital industry.
Through its 135+ best-in-class facilities, the business operates the most extensive hospital network in France serving two million patients annually and thanks to investment in its infrastructure and operations, Elsan also leads the field in innovation on both a medical and an operational basis.

A major player in the healthcare sector in France, ELSAN is active in all disciplines of the hospital profession and has a strong presence throughout the country. Twenty-eight thousand employees and 7,500 doctors work in 217 clinics and centers, treating over 5 million patients a year.

ELSAN: leader in the private hospital sector with the development of a unique network of health facilities close to 45 millions of French people.
#1 private healthcare operator in France.

4.2 Barclays has served as financial advisor on this transaction. The Board
and management, with the assistance of Barclays, will continue to explore
potential strategic actions to maximize value for shareholders.
Ongoing work with Barclays as exclusive financial advisor to explore
additional strategic opportunities to create shareholder value.
4.3 Wilke Farr & Gallagher LLP has served as legal counsel on the
Agreement.

5. More on CVC:
CVC invests in high-quality, cash-generative and growing businesses with:
• Defendable and leading market positions
• Significant and predictable cash flows
• Diverse products and services that customers require in good and bad times
• Competitive leadership in terms of products, innovations, know-how and cost structures
• Well-diversified customer bases, diverse products and broad geographic footprints

CVC PRIVATE EQUITY

CVC-PE is an open-ended, private equity investment vehicle investing directly into companies and other private assets alongside CVC's private equity funds.
https://www.cvc-pe.com/

This Website and the materials herein are intended for certain types of investors only and to persons in certain jurisdictions where the strategy is authorised for distribution.

Please choose from the following countries. By selecting a country from the list below, you certify that you are resident in that country. Should you be resident in a country that is not listed below, you cannot access the content of this Website.
Sleven: I do not meet the criteria to access this Website.

Finally, to Karim Mikhaël’s BOLD website the BOD has introduced a succinct but interesting change, it now reads in cap size:
CONFIDENT. PERSISTENT. BOLD.

Best.